Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Issue 6 (14th February 2020)

• Record Type: Journal Article
• Authors: Packer, Roger J; Iavarone, Antonio; Jones, David T W; Blakeley, Jaishri O; Bouffet, Eric; Fisher, Michael J; Hwang, Eugene; Hawkins, Cynthia; Kilburn, Lindsay; MacDonald, Tobey; Pfister, Stefan M; Rood, Brian; Rodriguez, Fausto J; Tabori, Uri; Ramaswamy, Vijay; Zhu, Yuan; Fangusaro, Jason; Johnston, Stephen A; Gutmann, David H
• Is Part Of: Neuro-oncology. Volume 22:Issue 6(2020)
• Page Start: 773
• Page End: 784
• Publication Date: 2020-02-14
• Subjects: gliomas -- immunotherapy -- molecular-targeted therapy -- neurofibromatosis type 1 -- pilocytic astrocytomas; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa036
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Gliomas are the most common primary central nervous system tumors occurring in children and adults with neurofibromatosis type 1 (NF1). Over the past decade, discoveries of the molecular basis of low-grade gliomas (LGGs) have led to new approaches for diagnosis and treatments. However, these new understandings have not been fully applied to the management of NF1-associated gliomas. A consensus panel consisting of experts in NF1 and gliomas was convened to review the current molecular knowledge of NF1-associated low-grade "transformed" and high-grade gliomas; insights gained from mouse models of NF1-LGGs; challenges in diagnosing and treating older patients with NF1-associated gliomas; and advances in molecularly targeted treatment and potential immunologic treatment of these tumors. Next steps are recommended to advance the management and outcomes for NF1-associated gliomas.